Neumora Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $176,065 | $200,927 |
| General and administrative | 60,091 | 62,537 |
| Acquired in-process research and development | 5,000 | — |
| Total operating expenses | 241,156 | 263,464 |
| Loss from operations | (241,156) | (263,464) |
| Other income (expense): | ||
| Interest income | 8,344 | 19,933 |
| Interest expense | (3,219) | — |
| Other expense, net | (767) | (78) |
| Total other income | 4,358 | 19,855 |
| Net loss before income taxes | (236,798) | (243,609) |
| Provision for income taxes | 130 | 178 |
| Net loss | $(236,928) | $(243,787) |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on marketable securities | (62) | 138 |
| Comprehensive loss | $(236,990) | $(243,649) |
| Net loss per share, basic and diluted | $(1.45) | $(1.53) |
| Weighted-average shares outstanding, basic and diluted | 163,391 | 159,377 |
The accompanying notes are an integral part of these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.